Overall rank by patents
#9,811
of 50,000 tracked assignees
USPTO PatentsView assignee record - 32 granted patents across 6 technology areas, recorded in grant years 2020–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (HETEROCYCLIC COMPOUNDS).
The verdict
According to USPTO PatentsView, Kymera ranks #9,811 of 50,000 tracked US assignees by granted-patent volume, with 32 patents across 6 technology areas.
USPTO PatentsView assignee plate
Corpus R9811 · US Corporation #9,811 · 32 grants
GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH
Nearest grant-volume peer: Jvis-usa, Llc (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Basell Polyolefine · near
52 score
Kymera Therapeutics · this assignee
52 score
Mloptic · near
52 score
Teleflex Life Sciences · near
52 score
The Catholic Univers… · near
52 score
3D Lighting Innovati… · lowest
7 score
What this shows Kymera Therapeutics, Inc. stamps GRANTS-SMALL, UPPER-Q, PHOTO-FINISH, CPC-NARROW, INNOV-PAR, CLAIMS-RICH, TYPE-USCORP, SPAN-YRS, BOOK-RICH. Volume places it #9,811 of 50,000; Innovation Score 51.7/100 sits in the top 11% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is Jvis-usa, Llc (±0 grants).
Kymera Therapeutics, Inc. has been granted 32 US utility patents between 2020 and 2025, placing Kymera Therapeutics, Inc. at #9,811 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.2 claims per patent with primary concentration in C07D (HETEROCYCLIC COMPOUNDS). As a US Corporation, Kymera Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Kymera sits between Jvis-usa, Llc (32 patents, rank #9,806) and Mastercard Mobile Transactions Solutions, Inc. (32 patents, rank #9,814) - the closest US assignees by grant volume. The composite Innovation Score of 51.7/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Grant cadence records the difference between two grant-year windows. Historical data spans 2020 through 2025, with 32 total grants over that period. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.
Claim depth and technology breadth describe this aggregate record. Kymera Therapeutics, Inc.'s 18.2 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 6 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
JVIS-USA, LLC
32 patents
KNOW Bio, LLC
32 patents
KYLAND TECHNOLOGY CO., LTD.
32 patents
Kura Oncology, Inc.
32 patents
LABINAL POWER SYSTEMS
32 patents
Lancer Corporation
32 patents
LedEngin, Inc.
32 patents
MASTERCARD MOBILE TRANSACTIONS SOLUTIONS, INC.
32 patents
Kymera Therapeutics, Inc.
32 patents
What this shows Kymera holds 32 patents at rank #9,810, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #9,810 in granted patent volume.
Other assignees with the most granted patents in Kymera's primary technology class.
Two PlainPatent-derived peer sets for Kymera, neither rank-band nor same-CPC leaders (those blocks stay above).
Nearest assignees by Innovation Score (52 here).
Kymera's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
52 Top 11% higher than 89% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 1 | 3.1% |
| 2021 | 1 | 3.1% |
| 2022 | 7 | 21.9% |
| 2023 | 10 | 31.3% |
| 2024 | 11 | 34.4% |
| 2025partial year | 2 | 6.3% |
Top 6 of 6 technology areas
Overall rank by patents
#9,811
of 50,000 tracked assignees
51.7 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.